*ST Zhong Rong (000982): Signing Strategic Cooperation Agreement With Kang Ming Bai To Jointly Promote The Development Of "Mebs-Lg" Platform

*ST 000982.SZ announced that in February 23, 2020, the company signed a strategic cooperation framework agreement with Beijing Kangming Bai Ao new drug research and Development Co., Ltd. ("Kangming Bai Ao") in Beijing, and jointly promoted the development of the platform of "Mebs-lg" (antibody specific bispecific antibody) platform, and chose the CDMO platform in China to provide a one-stop way for customers to achieve new drug research and development. Strategic cooperation in technical services.

Kang Ming Bai Austria was founded in January 20, 2014, is an innovation driven company dedicated to the development of innovative antibody drugs. Kang Ming Bai focuses on the demand for antibody drugs and technology in the areas of malignancy, immune system diseases, infectious diseases, major epidemics, etc., focusing on the development of proprietary monoclonal antibodies and biological analogues of proprietary intellectual property rights. The platform carries out the screening and research of new antibody.

For the company, the health care industry is a new field. The foreign investment target company is an excellent enterprise in the field of immunotherapy, with strong R & D capability and excellent product system. According to the national development plan, the company will grasp investment opportunities in a timely manner. Through this cooperation, we will make full use of the advantages of the cooperative enterprises in the medical and health field and further optimize the integration of resources with the advantages of the listed companies. It is expected to open up new growth points, enhance the overall profitability and create opportunities for the rapid development of the listed companies.